Semler Scientific

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Semler Scientific posts record revenue and profit growth in Q4

Semler Scientific delivered robust financial performance in Q4 2022, marked by record revenue, profit growth, and a strong cash position.
The company's strengths lie in its revenue diversification, profitability improvement, and strategic leadership transition.
Challenges include managing operating expenses, sustaining revenue growth across segments, and ensuring a smooth CEO transition.
Opportunities for Semler include expansion, innovation in healthcare technologies, and leveraging market demand for its services for future growth.

Semler Scientific achieves record Q1 earnings amidst strategic growth

Semler Scientific delivered robust financial performance in Q1 2023, marked by record revenue and pre-tax net income, underpinned by strong liquidity.
The company's strategic focus on governance, product innovation, and confidence in product benefits positions it well to navigate challenges and seize growth opportunities.
Despite cost management challenges and regulatory uncertainties, Semler's resilience, financial strength, and commitment to innovation bode well for future success.

Semler Scientific reports record revenue and profit growth in Q2

Semler Scientific's Q2 2023 performance showcased robust revenue growth, driven by successful QuantaFlo sales, and a significant increase in pre-tax net income.
The company's strategic initiatives, including leadership changes, product introductions, and operational streamlining, demonstrate a focus on sustainable growth and innovation.
While facing challenges such as cost management and workforce reduction, Semler Scientific is well-positioned to leverage opportunities in market expansion, technology advancements, and clinical benefits delivery.

Semler Scientific excels in Q3 with strong revenue growth

Semler Scientific's Q3 2023 earnings call highlighted robust financial performance, operational efficiency, and growth opportunities. The company's focus on innovation and market expansion positions it well for future success.

Semler Scientific reports solid Q4 earnings, eyes growth in cardiovascular diagnosis

Semler Scientific's Q4 2023 earnings call showcased positive financial performance, strategic growth initiatives, and a commitment to innovation in cardiovascular disease diagnosis.
Despite challenges such as operating expenses and fixed fee revenue decline, the company's adaptability and focus on clinical benefits position it well for future opportunities.
Analyst inquiries and executive responses highlighted a strong emphasis on efficiency improvements, market adaptability, and regulatory clearances for continued growth.

Semler Scientific reports earnings growth, eyes new product clearance

Semler Scientific's Q1 2024 performance showed growth in earnings and effective cost management.
While facing revenue challenges, the company is strategically positioned to capitalize on growth opportunities.
With a focus on innovation and market expansion, Semler aims to drive future revenue growth.
The company's strong financial position and strategic initiatives position it well for future success.

Semler Scientific adopts bitcoin treasury, reports stable Q2 performance

Semler Scientific's Q2 2024 performance reflects a strategic shift towards bitcoin as a treasury asset and a focus on core business operations.
While facing revenue challenges and cost management needs, the company's financial strength and flexibility position it well for future growth.
Opportunities lie in leveraging debt securities for expansion and capitalizing on the potential of bitcoin as a long-term investment.

Semler Scientific reports robust Q3 earnings, diversifies into Bitcoin

Semler Scientific's Q3 2024 performance reflects resilience in income generation and prudent cost control measures.
The company's strategic focus on Bitcoin acquisitions and product innovation positions it for potential growth and market leadership.
While facing revenue challenges and financial risks, Semler's exploration of financing options and regulatory compliance efforts signal a proactive stance.
Opportunities lie in leveraging operational strength for expansion, diversifying investment strategies, and capitalizing on early disease diagnosis capabilities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.

Semler Scientific, Inc. (SMLR) CEO Doug Murphy-Chutorian on Q1 2020 Results - Earnings Call Transcript

HealthEquity

Pinterest

It's time to get greedy with these beaten-down businesses.

Got $3,000? Buy These 3 Coronavirus Bear Market Bargains

Semler Scientific, Inc. (SMLR) CEO Doug Murphy-Chutorian on Q4 2019 Results - Earnings Call Transcript

Beyond Meat

Fulgent Genetics

These three companies are all growing like gangbusters and have already reached profitability.

Hypergrowth or Profits? These 3 Stocks Don't Make You Choose

LeMaitre Vascular

We take a look at three small and promising healthcare companies across diagnostics, surgical products, and genetic testing.

3 Exciting Healthcare Stocks

News for Semler Scientific Stock (SMLR)